HTMwire
Claroty / Medigate logo

Claroty / Medigate

Device Security Platforms

HTMwire assessment

Healthcare IoT security platform with device discovery, vulnerability management, and threat detection for 900+ device types. Best in KLAS winner.

Key Features

  • Passive device discovery and classification for 900+ medical device types
  • Real-time vulnerability and risk assessment with clinical context
  • Network microsegmentation policy recommendations
  • Threat detection with behavior baselining
  • Integration with CMMS, NAC, SIEM, and firewall platforms

What It Helps You Do

Passive device discovery Clinical-context risk scoring Network microsegmentation Threat detection

What Sets Them Apart

Four consecutive Best in KLAS awards for Healthcare IoT Security — widest medical device coverage with passive-only discovery that doesn't disrupt clinical workflows.

How Claroty / Medigate Uses AI

Uses AI/ML Machine LearningBehavioral analytics

HTMwire's independent read on the technology — not the vendor's marketing claim.

Uses ML-powered deep packet inspection for passive device classification and behavioral profiling. Machine learning models baseline normal device communication patterns to detect anomalies and threats without active scanning.

  • DPI-based device classification. Machine learning over deep packet inspection passively fingerprints 900+ medical device types from network traffic.
  • Behavioral anomaly detection. Baselines normal device communication patterns to flag deviations and threats without active scanning.

Key Numbers

  • Best in KLAS Healthcare IoT Security 5 years running; 95.4/100 in 2025
  • $150M Series F (Jan 2026), more than $735M raised to date
  • Analyzed 2.25M+ IoMT and 647K+ OT devices across 351 healthcare organizations

Integrations

ServiceNow CrowdStrike Palo Alto Networks Cisco ISE Accruent TMS

Tags

iomt-security device-discovery vulnerability-management network-monitoring

Trust Signals

Founders
Co-founded in 2015 by Amir Zilberstein (co-founder of Waterfall Security Solutions), Benny Porat, and Galina Antova; incubated by the Team8 foundry.
Customers
2,000+ hospitals and clinics worldwide
Reviews
Best in KLAS Healthcare IoT Security, 4 years running (score 95.4/100)
Certifications
SOC 2 Type II
Investors / Funding
Backed by Bessemer Venture Partners, SoftBank Vision Fund 2, Rockwell Automation, Schneider Electric, and Siemens; $150M Series F led by Golub Growth (Jan 2026), $735M+ raised to date.

Frequently Asked Questions

Is Claroty xDome (Medigate) passive or active device discovery?

Passive. Claroty discovers and classifies medical and OT devices using network-based deep packet inspection (DPI) and behavioral attributes, observing traffic rather than actively probing devices, which avoids disrupting patient-connected equipment.

Has Medigate / Claroty won Best in KLAS for Healthcare IoT Security?

Yes. Claroty xDome (formerly Medigate) was the Best in KLAS winner for Healthcare IoT Security for five consecutive years through 2025, scoring 95.4 out of 100 in the 2025 report based on 42 healthcare organizations. In the 2026 report Claroty was named a Top Performer with a 92.5 score from 35 organizations.

What systems does Claroty integrate with for HTM and security teams?

Claroty integrates with existing CMMS, NAC, SIEM, and firewall infrastructure, including ServiceNow, Cisco ISE, Palo Alto Networks, CrowdStrike, and Accruent TMS, so device inventory and risk data flow into the tools HTM and security teams already use.

Who funds Claroty and is it financially stable?

Claroty is a well-capitalized private company. It raised a $150M Series F in January 2026 (led by Golub Growth) on top of more than $735M in prior funding, with backers including Bessemer Venture Partners, SoftBank Vision Fund 2, Rockwell Automation, Schneider Electric, and Siemens.

Sources

  1. Claroty wins Best in KLAS for Healthcare IoT Security five years in a row (95.4/100)
  2. Claroty secures $150M Series F (Jan 2026)
  3. Claroty $100M strategic growth financing, $735M total to date

We cite a primary or named source for every claim on this page. How we evaluate →

Last updated: June 9, 2026